טוען...
Immunotherapy Trials for Type 1 Diabetes: The Contribution of George Eisenbarth
Type 1 diabetes (T1D) results from the autoimmune destruction of pancreatic β-cells, and as such it should respond to immunotherapy. George Eisenbarth gave many significant contributions to this field. He has been involved at some level in most immunotherapy trials during the past three decades. He...
שמור ב:
| Main Authors: | , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Mary Ann Liebert, Inc.
2013
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3676656/ https://ncbi.nlm.nih.gov/pubmed/23786294 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/dia.2013.0107 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|